Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The focus of this study is to evaluate the efficacy, safety, and tolerability of veliparib in women with previously untreated, Stage III or IV, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer.

I'M INTERESTED

This research study is led by Dr. Tashanna Myers.

Contact: Laura Sorci, 413-794-3188

Participation details:

July 14, 2015
751051
Cancer-Gynecologic, Cancer
Baystate Medical Center, 759 Chestnut St, Springfield, MA

Inclusion Criteria:

  • Histologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, with the appropriate tissue available for histologic evaluation.
  • High-grade serous adenocarcinoma
  • Willing to undergo testing for gBRCA.
  • Adequate hematologic, renal, and hepatic function.

Exclusion Criteria:

  • Endometrioid adenocarcinoma, carcinosarcoma, undifferentiated carcinoma, mixed epithelial adenocarcinoma, adenocarcinoma not otherwise specified, mucinous adenocarcinoma, clear cell adenocarcinoma, low-grade serous adenocarcinoma, or malignant Brenner's tumor.
  • Participants with any evidence of other invasive malignancy being present within the last 3 years (with the exception of non-melanoma skin cancer). Participants are also excluded if their previous cancer treatment contraindicates this protocol's therapy.
  • Received prior radiotherapy to any portion of the abdominal cavity or pelvis.
  • Received prior chemotherapy for any abdominal or pelvic tumor.
Active
Interventional (Clinical Trial), Randomized
3